A clinical decision support tool that monitors changes in blood-based tumor mutational burden (bTMB)—the number of mutations in the tumor's DNA found in the blood—to identify early signs of drug resistance. It helps oncologists detect molecular progression via liquid biopsies before it becomes visible on medical imaging.
The framework reveals a high-potential clinical tool that leverages the proven lead-time of ctDNA over imaging, but faces a critical internal tension between overall bTMB and specific VAF metrics. While the market tailwinds for precision oncology are strong, the tool's success depends on overcoming the biological detection limits of low-shedding tumors.
Strengths4
Weaknesses3
Opportunities3
Threats3
Essential for balancing the high clinical utility of early resistance detection against the internal technical limitations of ctDNA sensitivity and detection limits. · Generated 2026-10-08 by cavi/gemma4-31b-it-awq-4bit-32kAI-generated